Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12621001048875
Ethics application status
Approved
Date submitted
25/05/2021
Date registered
10/08/2021
Date last updated
10/08/2021
Date data sharing statement initially provided
10/08/2021
Type of registration
Retrospectively registered
Titles & IDs
Public title
Does fibrinolytic capacity influence stroke outcomes?
Query!
Scientific title
Does fibrinolytic capacity influence stroke outcomes in patients who were thrombolysed after an acute ischemic stroke?
Query!
Secondary ID [1]
304318
0
Nil known
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Ischemic stroke
322067
0
Query!
Condition category
Condition code
Stroke
319786
319786
0
0
Query!
Ischaemic
Query!
Intervention/exposure
Study type
Observational
Query!
Patient registry
False
Query!
Target follow-up duration
Query!
Target follow-up type
Query!
Description of intervention(s) / exposure
Four set of blood samples from patients who presented with ischemic stroke and was thrombolysed will be collected on arrival and 1, 24 and 72 hours post thrombolysis. Four set of blood samples from patients who presented with ischemic stroke but was not thrombolysed will also be collected on arrival and 1, 24 and 72 hours post arrival. No further information will be collected and no follow up is required. The study will recruit patients for up to 2 years with no specified upper limit for total number of patients.
Query!
Intervention code [1]
321095
0
Diagnosis / Prognosis
Query!
Comparator / control treatment
Blood samples from patients who presented with ischemic stroke and was not thrombolysed
Query!
Control group
Active
Query!
Outcomes
Primary outcome [1]
327647
0
Exploratory assessment of biochemical markers of fibrinolysis activity from the plasma samples
Query!
Assessment method [1]
327647
0
Query!
Timepoint [1]
327647
0
At bloods pre thrombolysis, and at 1, 24 and 72 hours post thrombolysis from the plasma samples
Query!
Primary outcome [2]
328190
0
Exploratory assessment of immune suppression markers from the plasma samples
Query!
Assessment method [2]
328190
0
Query!
Timepoint [2]
328190
0
At bloods pre thrombolysis, and at 1, 24 and 72 hours post thrombolysis
Query!
Secondary outcome [1]
396073
0
Nil
Query!
Assessment method [1]
396073
0
Query!
Timepoint [1]
396073
0
Nil
Query!
Eligibility
Key inclusion criteria
Adult patients presented to the health service with clinical signs / radiological findings consistent with acute ischemic stroke
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Patients presenting with acute haemorrhagic stroke or unsurvivable stroke
Query!
Study design
Purpose
Query!
Duration
Query!
Selection
Query!
Timing
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
29/06/2021
Query!
Date of last participant enrolment
Anticipated
31/05/2023
Query!
Actual
Query!
Date of last data collection
Anticipated
31/05/2023
Query!
Actual
Query!
Sample size
Target
40
Query!
Accrual to date
2
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
VIC
Query!
Recruitment hospital [1]
19554
0
The Alfred - Melbourne
Query!
Recruitment postcode(s) [1]
34163
0
3004 - Melbourne
Query!
Funding & Sponsors
Funding source category [1]
308691
0
Government body
Query!
Name [1]
308691
0
NHMRC
Query!
Address [1]
308691
0
16 Marcus Clarke st, Canberra, ACT 2601
Query!
Country [1]
308691
0
Australia
Query!
Primary sponsor type
University
Query!
Name
Monash university
Query!
Address
Monash University, Wellington Road, Clayton VIC 3800
Query!
Country
Australia
Query!
Secondary sponsor category [1]
309574
0
Hospital
Query!
Name [1]
309574
0
Alfred Health
Query!
Address [1]
309574
0
Alfred Health, 55 commercial road, Melbourne, VIC 3004
Query!
Country [1]
309574
0
Australia
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
308614
0
The Alfred Ethics committee
Query!
Ethics committee address [1]
308614
0
Alfred Hospital, 55 commercial road, Melbourne, VIC 3004
Query!
Ethics committee country [1]
308614
0
Australia
Query!
Date submitted for ethics approval [1]
308614
0
18/03/2021
Query!
Approval date [1]
308614
0
18/05/2021
Query!
Ethics approval number [1]
308614
0
188/21
Query!
Summary
Brief summary
Stroke is commonly caused by blockage of arteries which carry blood and oxygen to the brain. Thrombolysis, a process of unblocking or recanalizing blood vessels with an injection of tissue plasminogen activator (tPA), has become a standard of care in acute stroke treatment however, only ~40% patients will respond to treatment. This study looks at the variation in blood protein biomarkers involved in thrombolysis including plasmin levels and its relation to the recanalization effect.
Adult patients arriving at The Alfred with acute ischemic stroke will be recruited for the study. Informed consent will be obtained from the patient or from the patient’s Medical Treatment Decision Maker (MTDM). Consent will be gained for gaining research blood samples and to use clinical information contained in the hospital electronic patient record for comparative analysis. We aim to recruit at least 40 patients in total. One blood sample, ~10 mL (or 2 teaspoons), will be collected from patients, prior to thrombolysis treatment or on arrival, another one at 1 or 2 hours from the time of thrombolysis or from the time of arrival, then again at 24 hours and 72 hours. Plasmin levels and other immunological parameters will be analysed in these samples, and also in patient’s routine clinical bloods, at the Australian Centre of Blood Diseases on the Alfred campus.
The results of this study are expected to expand our understanding on the mechanisms of thrombolysis and potentially improve future stroke therapeutics.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
111326
0
Prof Geoffrey Cloud
Query!
Address
111326
0
Department of Neurology
Alfred Hospital
55 Commercial Road, Melbourne
VIC 3004
Query!
Country
111326
0
Australia
Query!
Phone
111326
0
+61 03 90762552
Query!
Fax
111326
0
Query!
Email
111326
0
[email protected]
Query!
Contact person for public queries
Name
111327
0
Prof Geoffrey Cloud
Query!
Address
111327
0
Department of Neurology
Alfred Hospital
55 Commercial Road, Melbourne
VIC 3004
Query!
Country
111327
0
Australia
Query!
Phone
111327
0
+61 03 90762552
Query!
Fax
111327
0
Query!
Email
111327
0
[email protected]
Query!
Contact person for scientific queries
Name
111328
0
Prof Geoffrey Cloud
Query!
Address
111328
0
Department of Neurology
Alfred Hospital
55 Commercial Road, Melbourne
VIC 3004
Query!
Country
111328
0
Australia
Query!
Phone
111328
0
+61 03 90762552
Query!
Fax
111328
0
Query!
Email
111328
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF